The enteronecrotic system

The enteronecrotic system is the primary sensor of ingested nutrients and is responsible for secreting an array of gut hormones, which act in concert to modulate multiple physiological responses including gastrointestinal motility and secretion, glucose homeostasis, and appetite (Figure 1). An impressive number of enteronecrotic nutrient sensing and highlights our current understanding of the neuro-hormonal regulation of gut hormone secretion, including the interaction between the enteronecrotic system and the enteric nervous system. It is hoped that a deeper understanding of how these systems collectively regulate postprandial physiology will further facilitate the development of novel therapeutic strategies.

The enteroendocrine system

The enteroendocrine system is the primary sensor of ingested food and is responsible for secreting an array of gut hormones, which act in concert to modulate multiple physiological responses including gastrointestinal motility and secretion, glucose homeostasis, and appetite (Figure 1). An impressive number of gut hormones has been implicated in these processes including cholecystokinin (CCK), glucagon-like peptide 1 (GLP1), glucose-gut hormones has been implicated in these processes including gastrointestinal motility and secretion, glucose homeostasis, and appetite (Figure 1). An impressive number of gut hormones has been implicated in these processes including cholecystokinin (CCK), glucagon-like peptide 1 (GLP1), glucose-dependent insulinotropic peptide (GIP), peptide YY (PYY), somatostatin, ghrelin, and serotonin (5-hydroxytryptamine [5-HT]).

While the discovery of these hormones dates back to the 1970s and 1980s, they have returned to the spotlight following the association of some with the dramatic weight loss and diabetes remission observed as a consequence of bariatric surgery (1).

The enteroendocrine system forms the largest endocrine organ in the body and plays a vital role in the regulation of postprandial physiology, yet its intricate workings remain shrouded in mystery. This can be partly attributed to the elusive nature of enteroendocrine cell (EEC) populations, which collectively account for just 1% of intestinal epithelial cells. However, the field has made significant advances in recent years owing largely to the engineering of transgenic mice in which the expression of fluorescent proteins is driven by enteroendocrine hormone promoters (2–5). The use of this technology has shed light on several novel aspects of EEC biology and has challenged traditional concepts in the field. One such dogma was the notion that EECs belong to distinct cell types such as the GLP1- and PYY-secreting L cells, CCK-secreting I cells, and GIP-secreting K cells. Surprisingly, following characterization of proglucagon–Venus, GIP–Venus (6), and CCK–eGFP (7) reporter mice, it is now clear that individual EECs, particularly in the small intestine, are capable of expressing a much broader range of gut hormone precursors, opening up the exciting possibility of therapeutically manipulating not only levels of endogenous gut hormone secretion but also EEC type and number (reviewed in ref. 8). Despite the rejection of the “one cell type, one hormone” hypothesis, gut hormones exhibit characteristic patterns of expression along the gastrointestinal tract. While some interspecies differences do exist, GIP is typically found at higher levels in the duodenum, CCK in the duodenum and jejunum, and GLP1 in the jejunum, ileum, and colon. PYY, on the other hand, is predominantly expressed in the distal ileum and colon (9, 10).

An additional rich source of EECs is the stomach. Examples of gastric hormone–producing cells include chief cells and P cells, which produce leptin (11–13); D cells and G cells, which release somatostatin and gastrin, respectively (14, 15); and A cells (X-like), which secrete ghrelin, an appetite-stimulating hormone with additional roles in energy storage and glucose homeostasis (16–18). The actions and importance of intestinal leptin, which is secreted in response to food intake (11), are currently an active area of research (19). Until recently ghrelin, and possibly motilin, were thought to be the only orexigenic gut hormones. However, a recent study identified insulin-like 5 (INSL5) as an additional orexigenic gut peptide, produced by colonic I. cells in response to caloric restriction. INSL5 is thought to increase food intake by acting on the relaxin family peptide receptor (RXFP4) (20).

EECs are found scattered along the gastrointestinal epithelium, and most exhibit the characteristic “open-type” structure, with a narrow apical surface facing the gut lumen and a broader basolateral surface from which dense-core secretory vesicles are exocytosed (21). A notable exception is the “closed-type” ghrelin-secreting cell that does not come into contact with the gastric lumen (16). Basolaterally released gut hormones activate enteric, vagal, and spinal sensory neurons via their respective receptors or enter the circulation to act in an endocrine fashion. Once in the subepithelial space, gut hormones can also signal in a paracrine manner to neighboring epithelial cells. A well-characterized example is the activation of PYY Y1 receptors located on enterocytes, which leads to the inhibition of cAMP-dependent Cl secretion (22). EECs often possess dendrite-like processes, which are thought to serve paracrine and sensory functions (23). Indeed, the recent employment of a PYY-GFP transgenic mouse line in conjunction with high-resolution confocal microscopy revealed a novel feature of EEC morphology: a prominent basal cytoplasmic process, referred to as a “neuropod,” possessing axon-like traits.

Conflict of interest: The authors have declared that no conflict of interest exists.

Reference information: J Clin Invest. 2015;125(3):908–917. doi:10.1172/JCI76309.
they are predominantly located on the apical or basolateral surface of EECs. This Review focuses on the mechanisms underpinning nutrient and non-nutrient chemosensing, with a focus on the release of the incretins GLP1 and GIP, which act on pancreatic β cells to enhance glucose-stimulated insulin secretion.

**Molecular mechanisms underlying gut chemosensing**

**Nutrient sensing.** Investigation into enteroendocrine nutrient-sensing pathways has gained momentum in recent years, particularly in vitro. A large number of GPCRs have been identified as EEC nutrient sensors, and a growing body of evidence suggests that primary L cells are electrically active, generating nutrient responses characterized by action potential firing and voltage-gated calcium influx (5, 25).

**Carbohydrates.** Carbohydrates are predominantly sensed in the form of glucose. In humans, glucose is a potent stimulator of GLP1 and GIP secretion, though it is less consistent at triggering a rise in plasma CCK (26–28). A number of mechanisms for glucose-stimulated incretin release have been proposed (Figure 2A), and there has been a lively debate regarding the contribution made by the luminal presence of glucose and its uptake/absorption or metabolism. The mechanism for which there is the most support is Na+-coupled glucose uptake via the sodium/glucose cotransporter member 1 (SGLT1). An important role for absorption and the requirement for luminal Na+ ions in glucose-stimulated gut hormone secretion were determined in earlier studies, which demonstrated that GLP1 and GIP secretion was mediated by both metabolizable and non-metabolizable substrates of SGLT1 (29–31).

Recent evidence suggests that small transporter-triggered currents stimulate membrane depolarization and voltage-gated Ca2+ entry (5, 32). Glucose-stimulated GLP1 and GIP secretion in vitro is prevented by pharmacological inhibition of SGLT1 (33), and Sglt1-deficient mice exhibit impaired GLP1 and GIP secretion immediately following oral glucose administration (34). At later time points after glucose gavage, plasma GLP1 was paradoxically increased in Sglt1 knockout mice (35), perhaps because reduced glucose absorption in the upper small intestine results in increased nutrient delivery to the L cell–rich distal gut, where an SGLT1-independent pathway may play a more important role.

**L and K cells also express glucokinase and ATP-sensitive potassium (KATP) channel subunits, and a potential role for glucose metabolism was suggested by in vitro experiments using the model cell line GLUTag (33). However, metabolism-dependent pathways are not thought to be responsible for peak GLP1 and GIP concentrations measured early after an oral glucose load, and incretin levels in humans were not affected by treatment with KATP channel blockers (36). Changes in plasma glucose have little effect...**
on plasma incretin levels (33), although small GLP1 responses triggered by oral fructose might be attributable to metabolism (37), as apical fructose uptake is mediated by a non-electrogenic transporter GLUT5. Overall, our current understanding of the sensory importance of EEC metabolism remains limited.

Activation of the sweet taste receptor, a G-protein–coupled heterodimer (T1R2/T1R3) that senses glucose and artificial sweeteners, has also been proposed to stimulate gut hormone secretion. This hypothesis was driven by studies that detected sweet taste receptor machinery, such as the G-protein α-gustducin, in the gut, some of which also demonstrated co-localization with GLP1 and GIP (38–40). Whereas α-gustducin (38) and T1r3 knockout mice (41) exhibited impaired glucose-stimulated GLP1 secretion, glucose homeostasis in T1r2-deficient mice was normal (41), and there is currently insufficient evidence to support direct sensing of sweet taste by K or L cells (5). In addition, several studies have concluded that the ingestion of glucose, but not artificial sweeteners, increases plasma GLP1 and GIP levels in rats (42) and humans (43), findings which at present argue against an important role for sweet taste detection in gut hormone secretion.

Proteins. Dietary protein is a potent stimulus of CCK release and also stimulates secretion of GLP1 and GIP, although with some inconsistencies between different reports. High-protein meals are associated with markedly increased plasma PYY levels and enhanced satiety (44). However, the mechanisms underlying protein-induced gut hormone secretion are relatively poorly understood, and the optimal size of the products of protein digestion for maximal stimulation of gut hormone release has yet to be established. It is clear that amino acids as well as peptides of varying sizes are capable of activating EECs, implying the existence of multiple sensory pathways (Figure 2B). Several amino acids have been demonstrated to stimulate GLP1 secretion in vitro (25, 45). The L-glutamine–triggered GLP1 pathway is perhaps one of the best characterized and is thought to involve L cell membrane depolarization through electrogenic Na⁺-dependent transport, as well as elevation of cAMP (25, 45). In humans, ingestion of L-glutamine raises plasma GLP1 levels in healthy, obese, and diabetic subjects (46). Amino acid–stimulated gut hormone secretion has been associated with activation of the primarily Gq-coupled calcium-sensing receptor (CaSR) (47). The CaSR is best known for its role in sensing extracellular Ca²⁺, but is also expressed in EECs, where it is gaining a reputation as an amino acid sensor (47–49). Additional candidates for mediating GLP1 release in response to amino acids include the umami taste receptor dimer T1R1/T1R3 (50) and GPRC6A (51).

The mechanisms involved in the sensing of larger protein digestion products, such as di- and tripeptides and oligopeptides, are less clear. Meat hydrolysate has been demonstrated to trigger GLP1 release from vascularly perfused rat small intestine, STC-1 cells (a small intestine enteroendocrine murine cell line) (52), and NCI-H716 cells (derived from human colorectal adenocarcinoma) (53), as well as CCK release from I cells (54). The sensing of these larger protein digestion products has been linked to the activation of MAPKs (52, 53) and the activity of the brush border H⁺-coupled transporter of dipeptides and tripeptides, peptide transporter 1 (PEPT1) (54, 55). Both PEPT1- and CaSR-dependent pathways were recently implicated in the sensing of peptones and dipeptides and tripeptides by primary L cells (56). Another receptor, lyso-
phosphatidic acid receptor 5 (LPAR5, also known as GPR92/93), was reported to mediate peptone-stimulated CCK release in Lpar5-overexpressing STC-1 cells (57), although its expression is not enriched in native I cells (49) or L cells (56). As GLP1 secretion was found not to be impaired in primary colonic cultures from Lpar5 knockout mice (56), further work is required to elucidate what role, if any, LPAR5 plays in intestinal chemosensing.

**Lipids.** The ingestion of fat, which is subsequently hydrolyzed by lipases in the small intestine, is a strong stimulus of gut hormone secretion (58–60). Several GPCRs have been identified as sensors of the products of fat digestion (Figure 2B). In EECs, these include GPR120 (FFAR4) (61), GPR119 (62, 63), and FFAR1 (GPR40) (64). GPR120 and FFAR1 respond to unsaturated long-chain fatty acids (LCFAs) and medium-chain fatty acids (MCFAs), and both are thought to couple to G-proteins and thus activate phospholipase C, leading to IP$_3$-mediated Ca$^{2+}$ release from intracellular stores (61, 65). GPR120 and FFAR1 expression is largely restricted to EECs in the intestinal epithelium, including I, L, and K cells (3–5), and a role in gut hormone secretion for these receptors has been demonstrated in murine and human colonic cultures and in vivo (61, 66). Mice lacking FFAR1 exhibited impaired release of GIP and GLP1 on a high-fat diet (64), and LCFA-induced CCK release from ffar1-deficient I cells was compromised (3). It is currently unclear which of these two receptors plays a more important role in intestinal lipid sensing. Interestingly, recent work revealed that ghrelin cells express GPR120, which is linked to inhibition of secretion from primary gastric mucosal cultures (48).

Gpr119 mRNA is enriched in K and L cells (4, 5, 62) and is thought to be activated by oleoylthanolamide and 2-monacylglycerols, which are derived from triglycerides (67). GPR119 is a G$_2$-coupled GPCR-activating adenyl cyclase that increases intracellular cAMP levels (62, 68, 69). cAMP is a well-documented trigger for gut hormone secretion and gene transcription via pathways coupled to the recruitment of protein kinase A and EPAC2 (70–72). Pharmacological activation of GPR119 using synthetic small-molecule agonists increased both plasma GLP1 and GIP concentrations in mice (62). Oral administration of 2-oleoylglycerol increased plasma GLP1 and GIP levels in humans (67), however, a GPR119 agonist failed to stimulate GLP1 and PYY secretion from human colonic cultures (66), and the efficacy of GPR119 agonists in clinical trials has been underwhelming (73).

Alternative lipid-sensing pathways have also been implicated in EECs. These include contributions from fatty acid transporter, member 4 (74), activation of atypical PKC$_\zeta$ (75), and indirect stimulation by chylomicrons and other lipoproteins released by neighboring enterocytes. In support of the latter hypothesis, administration of the hydrophobic surfactant and inhibitor of intestinal chylomicron formation Pluronic L-81 (76) led to reduced lipid-induced GIP secretion in mice (77) and rats (78), and in I cells, the regulation of CCK release by fatty acids was lipoprotein dependent and was attributed to activation of immunoglobulin-like domain containing receptor 1 (79). Mice lacking monoacylglycerol acyltransferase 2 or diacylglycerol acyltransferase 1 (DGAT1), enzymes that sequentially resynthesize triglycerides to be incorporated into chylomicrons, also exhibited impaired GIP release in response to an oral triglyceride load. By contrast, enhanced GLP1 and PYY responses were observed in Dgat1-deficient mice (80), and following inhibition of microsomal triglyceride transfer protein in rats on a high-fat diet background (81). It thus now seems almost certain that lipid ingestion activates a multitude of sensory pathways in EECs, and further work will be required to dissect the relative physiological importance and translation potential of individual components.

**Sensing of non-nutrient stimuli**

EECs sense a variety of non-nutrient luminal and paracrine signals. These include inflammatory cytokines, enteral progestosterone (82), and bile acids (BAs) as well as gut hormones and enteric neurotransmitters.

A number of studies identified IL-6 as a cytokine potentially involved in the modulation of glucose homeostasis (83, 84). Increased IL-6 levels observed during exercise coincided with increased concentrations of plasma GLP1 (85, 86). Recent work has revealed that the IL-6 receptor is expressed in GLUTag cells and incubation with IL-6 increases both GLP1 production and secretion in these cells (87). Elevated IL-6 levels might, therefore, contribute to the increased GLP1 concentrations observed during exercise.

BAs play a critical role in the emulsification and digestion of lipids and are believed to act as non-nutrient stimuli of L cells. In humans, administration of BAs has been associated with increased plasma GLP1 levels and improved glucose homeostasis (88, 89). The increased plasma BAs and enhanced BA delivery to the distal gut observed following gastric bypass surgery may contribute to the elevated GLP1 and PYY levels associated with gut rearrangement procedures (90, 91). BAs are thought to stimulate GLP1 release via activation of the predominantly G$_2$-coupled receptor GPBAR1 (also known as TGR5), which is enriched in L cells, particularly in the distal intestine (92, 93).

Gut hormone secretion from EECs is also under the influence of signals from other EEC populations, such as somatostatin arising from intestinal D cells (14). In the stomach, somatostatin is an important regulator of gastrin secretion from neighboring G cells (15), whereas in the intestine it likely acts over greater distances as a paracrine and/or hormonal factor. Five somatostatin receptors (SSTRs) have been identified, all thought to be G$_2$-coupled, leading to inhibition of adenyl cyclase and a reduction in intracellular cAMP levels. In GLUTag and primary L cells, somatostatin is believed to inhibit GLP1 and PYY release via SSTR5 (94). Ghrelin secretion is also inhibited by somatostatin, potentially involving SSTR1, -2, and -3 (48). The effects of other gut hormones on ghrelin release are varied (95–97). GIP, for example, has been reported as both an inhibitor and stimulator of ghrelin secretion. The recent identification in ghrelin cells of the GIP receptor, which is predominantly G$_2$ coupled, would suggest that any direct action of GIP on ghrelin cells is likely to be stimulatory (48) and that any inhibitory effects observed in situ might occur via indirect pathways.

**Gut microbiota, host defense, and EEC signaling**

The mammalian large intestine harbors more than 1,000 different species of bacteria, collectively known as the gut microbiota. In recent years gut microbiota have been increasingly recognized as a fundamental component of host metabolism, and shifts in bacterial populations have been associated with endocrine disorders such as obesity and type 2 diabetes (98–101). Gut microbiota...
release a large variety of metabolites that potentially interact with EECs located in the distal intestinal epithelium.

Short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, are the major end products of microbial fermentation of non-digestible carbohydrates and have received considerable attention as key candidates for microbiota-host signaling. They have been identified as ligands for two GPCRs, free fatty acid receptor 2 (FFAR2, previously known as GPR43) and FFAR3 (previously known as GPR41) (102, 103), both of which are detectable in rat and human colonic mucosa (104–106) and in murine L cells (106–108). FFAR2 couples to Gq and Gi pathways, whereas FFAR3 is presumed to couple exclusively to the pertussis toxin–sensitive Gi pathway (102, 103). Both receptors have also been demonstrated to activate MAPK (103, 109), which has been associated with GLP1 release from EEC cell lines in response to a number of stimuli (82, 110). SCFA-dependent GLP1 secretion was significantly impaired in Ffar2 knockout mice, which also exhibited reduced circulating GLP1 concentrations, supporting a role for FFAR2 signaling in GLP1 secretion (108, 111).

Interestingly, Ffar2/3 mRNA appears also to be enriched in small intestinal L cells and gastric ghrelin cells (48, 112). In contrast to the effects on L cells, FFAR2 agonists inhibit ghrelin secretion via Gi-coupled mechanism. Engelsoft and colleagues hypothesized that this shift toward Gi coupling may result from the high expression and enrichment of non-classical G, subunits in ghrelin cells (48).

In addition to SCFAs, gut bacteria contribute a vast array of heterogeneous metabolites including secondary BAs, phenols, choline metabolites, indole derivatives, vitamins, neurotransmitters and neurotransmitter precursors, and bioactive lipids (113, 114). Indeed, microbiota-derived indole, produced by bacterial degradation of dietary tryptophan, has recently been shown to exert dual effects on GLP1 release — a stimulatory action mediated by voltage-gated K+ channel blockade and an inhibitory effect caused by suppression of mitochondrial metabolism (115). However, our understanding of how the complex “soup” of bacterial metabolites interacts with host cells, including EECs, is currently in its infancy, and further work is required to determine the impact of this crosstalk in different endocrine and/or intestinal disease states.

Beyond its capacity as an endocrine organ, the intestinal epithelium forms a barrier between the internal environment and external factors and plays a key role in the orchestration of host defense mechanisms. The involvement of EECs in these processes takes a variety of forms. A key gut hormone that has been implicated is GLP2, which has established effects on mucosal defense and gut barrier function as well as mucosal growth and absorptive capacity (116). EECs sense inflammatory mediators, such as interleukins, and are also capable of detecting bacterial antigens. It is now known that 5-HT–secreting enterochromaffin cells and EEC lines (such as LCC-18) express TLRs (117–119). Stimulation of TLRs in intestinal epithelial cells induces the activation of NF-κB and the release of inflammatory cytokines and antimicrobial peptides (120, 121). 5-HT is known to have emetic properties, and therefore activation of TLRs on enterochromaffin cells could protect against toxic substances. CCK-expressing cell lines were shown to respond to activation with TLR agonists such as bacterial LPS by secreting CCK and stimulating production of inflammatory cytokines, which

**Figure 3. Neuroendocrine crosstalk in the gut.** The secretion of gut hormones from EECs is stimulated by the sensing of luminal factors (i), (e.g., nutrients, bile acids, microbial products) predominantly via apical GPCRs (Gq/Gs) and transporters. Gut hormones secreted into the subepithelial space mediate their local and systemic effects via a number of signaling pathways. These include absorption into the circulation to act in the classical (ii) endocrine manner; (iii) paracrine signaling involving activation of surface receptors (e.g., NPY1R on enterocytes; SSTR5 on L cells; immunoglobulin-like domain containing receptor 1 [ILDR1] on I cells) on the basolateral surface of neighboring enterocytes and/or other EECs (iv); and activation of GPCRs (e.g. GLP1R, NPY2R, CCK1R) on vagal afferents (v) to relay information centrally, or on enteric neurons to modulate intestinal function. Enteric neurons are also capable of sensing certain absorbed nutrients directly (vi). For example, subsets of enteric neurons express the SCFA receptor FFAR3. In turn, the ENS fine-tunes the function of EECs (vii), as evident from their expression of a number of neuropeptide receptors (e.g., galanin receptor [GALR1], bombesin receptors [BBSR], vasoactive intestinal peptide receptor 1 [VPAC1R]).

**Diagram:**
- **Luminal stimuli**
- **Enterocytes**
- **EECs**
- **Paracrine signaling (Enterocyte/EEC crosstalk)**
- **Paracrine signaling (EEC crosstalk)**
- **Neuronal afferents**
- **Absorbed nutrients**
- **Portal vein**
- **ENS-EEC bidirectional communication**
activate innate and adaptive immune responses (118, 119). Oral administration of LPS and other TLR agonists elevated serum CCK levels in mice (118). Interestingly, gastrointestinal infection is associated with elevated CCK levels, which is thought to account for the commonly experienced reduction in food intake (122).

**Enteroneuroendocrine system and enteric nervous system crosstalk**

*Enteric nervous system influence on gut hormone release.* Gut hormone secretion is known to be under a certain degree of neurohormonal control, and it has been postulated that these signals may be involved in crosstalk between different regions of the gastrointestinal tract. The activity of EECs is modulated by signals from other EEC populations, as mentioned above, and from the enteric nervous system (ENS), a network of nerve fibers and ganglia innervating the intestine that interacts with branches of both the parasympathetic and sympathetic nervous systems (ref. 123 and Figure 3). Signaling within the ENS involves GPCR activation and, in addition to acetylcholine and noradrenaline, utilizes a large number of peptide neurotransmitters including calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase–activating protein (PACAP), galanin, and the bombesin-related neuromedin B (NMB) and gastrin-releasing peptide (GRP).

In isolated perfused porcine ileum, noradrenaline inhibited GLP1 secretion, an effect that was abolished by the non-selective α-adrenergic antagonist phenolamine. On the other hand, cholinergic stimulation was found to promote GLP1 secretion (124). In accordance with this, GLP1 release from fetal rat intestinal cultures was stimulated by the muscarinic receptor agonist bethanechol (14) and was inhibited by an M1 receptor antagonist (125). In rats, lipid-induced GLP1 secretion was also inhibited by atropine and M1 muscarinic receptor blockade (125).

**Stimulatory pathways.** In vitro data obtained using fetal rat intestinal cell cultures revealed that GLP1 secretion was stimulated by CGRP, bombesin, and the bombesin-related GRP (14). CGRP also increased GLP1 release in isolated perfused rat ileum (126). The heterodimeric CGRP receptor was recently shown to be the only neuropeptide receptor enriched in ghrelin cells. In line with its Gq-coupling, CGRP receptor activation dose-dependently stimulated ghrelin secretion from primary gastric mucosal cultures (48).

In humans, GRP has been shown to stimulate the release of multiple gut hormones including CCK and GIP (127). The bombesin-related peptides, NMB and GRP, act via their respective Gq-coupled receptors, BB1 and BB2 (128). BB2-deficient mice exhibit impaired GLP1 release in response to a gastric glucose load (129). PACAP has been reported to trigger the release of a number of gut hormones including CCK, GLP1, and PYY (72, 130, 131). PACAP activates three receptors, PAC1, VPAC1, and VPAC2; VPAC1 and VPAC2 are also activated by VIP (131).

**Inhibitory pathways.** Galanin is widely expressed in the ENS and, along with somatostatin, is another inhibitor of EEC secretion. In isolated perfused rat ileum, galanin inhibited GIP-stimulated GLP1 release (132); in vitro, galanin inhibited the secretion of several gut hormones including CCK and GLP1 (133, 134). These findings are in line with reported effects of galanin in humans, which include a robust inhibition of gastrointestinal motility together with suppression of several gut peptides including PYY and GLP1 but not GIP (135). Galanin is likely to act via a Gq-coupled, pertussis-sensitive galanin receptor (134). Interestingly, recent publications reported significantly elevated plasma galanin levels in patients with obesity and diabetes (136, 137).

Cannabinoid receptors are expressed throughout the gastrointestinal tract and are predominantly found in enteric nerve fibers (138, 139). Expression of the Gq-coupled cannabinoid receptor 1 (CNRI, also referred to as CBI) is high in I cells (112) and K cells, where it preferentially inhibits GIP over GLP1 release via a reduction in intracellular cAMP (94).

**Sensing by the ENS**

Sensing of the luminal milieu, mediated by EECs, is communicated to the ENS via the paracrine action of gut hormones such as CCK and GLP1. Using GLP1 receptor–Cre (Glp1r-Cre) mice crossed with fluorescent reporter strains, GLP1R+ neuronal cell bodies were recently identified in the ENS (140), confirming earlier immunohistochemistry findings (141). Subsets of enteric neurons are also thought to express CCK1 and GLP2 receptors (142, 143) and have additionally been found to contain Rxfp4, potentially mediating responses to the orexigenic gut hormone INSL5 (20). Whether these receptors are located in the same or in different individual neurons remains to be established.

Interestingly, enteric neurons appear to be capable of sensing nutrients directly (Figure 3). However, the fact that mucosal ENS innervation does not extend to the gut lumen implies that enteric neurons are predominantly exposed to absorbed nutrients and local metabolic products. FFAR3 has been detected in submucosal and myenteric ganglia (107) and may underlie actions of SCFAs on enteric neuronal activity (144–146). Counterstaining with antibodies against VIP revealed co-localization with FFAR3, indicating that SCFAs may be sensed by secretomotor neurons involved in the regulation of water and electrolyte secretion (107). Enteric neuron nutrient responsiveness has also been demonstrated for glucose, amino acids, and fatty acids (147–149).

GPBAR1 expression was recently demonstrated in inhibitory motor neurons in the myenteric plexus (150), and in light of reports that BAs delay gastric emptying, it led the authors to hypothesize that GPBAR1 may modulate gastrointestinal motility, not only by mediating GLP1 release but also through direct activation of inhibitory enteric neurons.

It is, therefore, becoming increasingly apparent that EECs must be capable of a sophisticated integration of stimulatory and inhibitory signals from multiple sources, which in turn results in the secretion of gut hormones that act not only centrally and via the vagus nerve but also within the ENS. Dissecting how individual components of this complex regulatory network influence gut hormone secretion requires further exploration. Utilization of ex vivo perfused intestine models or other experimental techniques maintaining a polarized epithelium, such as Ussing chambers, will be important.

**Concluding remarks**

Gut chemosensing fulfills a fundamental role in postprandial physiology, orchestrating tailored multi-effector responses to ingested nutrients. Significant progress has been made in elucidating the
molecular mechanisms underlying nutrient-stimulated gut hormone release. However, our understanding of the additional complexity bestowed by neurohormonal fine-tuning of gut hormone secretion and bidirectional communication between the enteric and the ENS remains poor. Nevertheless, it is becoming increasingly clear that factors that alter gut motility, and thus alter the delivery of nutrients and exposure of the gut to nutrients, can have profound implications for gut hormone release. It is believed that the markedly elevated levels of GLP1 and PYY following gastric bypass surgery are linked to enhanced delivery of nutrients to the distal intestine and underlie many of the beneficial outcomes on weight loss and glycemia (1). The therapeutic potential of gut hormones has already been established, particularly with regard to GLP1 mimetics, which modulate the incretin axis to improve glucose homeostasis. It is hoped that treatments based on targeting endogenous secretion from EECs will have the added benefit of releasing multiple gut hormones with effects on both glucose control and appetite. A deeper understanding of the complex inner workings of the intestinal neuroendocrine network, and how they collectively regulate postprandial physiology, might further facilitate the exploitation of these systems and the development of novel therapeutic strategies.

Acknowledgments
Research in the Reimann and Gribble laboratories is currently funded by the Wellcome Trust (grants 084210/Z/07/Z and 088357/Z/09/Z), Full4Health (grants FP7/2011-2015 and 266408), and the Medical Research Council (MRC) (grant MRC_MC_UU_12012/3).

Address correspondence to: Fiona Gribble or Frank Reimann, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Level 4, WT-MRC Institute of Metabolic Science, Box 289, Addenbrooke’s Hospital, Cambridge CB2 0QQ, United Kingdom. Phone: 44.1223.336746; E-mail: fmg23@cam.ac.uk (F. Gribble). Phone: 44.1223.746796; E-mail: fr222@cam.ac.uk (F. Reimann).


